By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:





Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 





Company News
FDA Accepts For Priority Review Bristol-Myers Squibb (BMY)’s Application For Opdivo (Nivolumab) In Previously Treated Hepatocellular Carcinoma 5/24/2017 11:31:18 AM
EMA Validates Application For Bristol-Myers Squibb (BMY)’s Sprycel (Dasatinib) In Children With Chronic Myelogenous Leukemia 5/19/2017 8:05:28 AM
Bristol-Myers Squibb (BMY) Research Showcases Expansive Oncology Clinical Development Program And Commitment To Exploring Novel Combinations At ASCO 2017 5/18/2017 8:44:38 AM
Bristol-Myers Squibb (BMY) And Calithera Biosciences (CALA) Expand Collaboration Evaluating Opdivo (Nivolumab) In Combination With CB-839 Into Non-Small Cell Lung Cancer And Melanoma 5/10/2017 10:25:31 AM
Veeva Systems, Inc. Release: Veeva Commercial Cloud To Help Bristol-Myers Squibb (BMY) Deliver More Efficient And Effective Customer Engagement 5/8/2017 11:17:22 AM
Don't Count Us Out: Pfizer (PFE) Hints at a Possible Bristol-Myers Squibb (BMY) Deal 5/3/2017 6:16:23 AM
Bristol-Myers Squibb (BMY)'s Oral, Interferon-free HCV Regimen Approved In China 5/1/2017 12:32:58 PM
European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) For Squamous Cell Cancer Of The Head And Neck In Adults Progressing On Or After Platinum-Based Therapy 5/1/2017 7:09:46 AM
Interview Insider: Tips on How to Get Hired at Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), and Novartis AG (NVS) 4/28/2017 2:51:33 PM
Filings Reveal Bristol-Myers Squibb (BMY) Passes on Option to Buy f-Star 4/28/2017 6:39:41 AM
12345678910...
//-->